The use of disease-modifying antirheumatic drugs (DMARDs) and the adoption of an early and aggressive treatment strategy have transformed the outcomes of patients with rheumatoid arthritis (RA). These immunosuppressive and immunomodulatory agents are essential to the comprehensive RA treatment strategy, with an objective of achieving disease remission or sustained minimal disease activity, to prevent radiographic progression.1
The DMARDs currently available are broadly categorized as conventional synthetic DMARDs (csDMARDs) and biologic DMARDs (bDMARDs). Conventional synthetic DMARDs typically include methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide, and are generally used in the first-line setting.2 Several bDMARDs are approved for RA in 6 therapeutic classes, including tumor necrosis factor inhibitors (etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab); T-cell costimulatory blocking agent (abatacept); B-cell depleting agents (rituximab); interleukin-1 receptor antagonists (anakinra); interleukin(IL)-6 inhibitors (tocilizumab and sarilumab); and Janus kinase inhibitors (JAK; tofacitinib, baricitinib, and upadacitinib).3 Biosimilars, a highly similar copy of the original approved biologic agent, with no clinically meaningful differences in safety, purity, and potency, has expanded the options of bDMARDs.4 In general, bDMARDs are prescribed after the failure of first-line csDMARD therapy.
The most commonly used csDMARD in the first-line setting is methotrexate. When RA progresses despite treatment with csDMARDs, a bDMARD may be introduced as monotherapy, typically in combination with a csDMARD, such as methotrexate. In cases of disease progression, despite treatment with methotrexate and bDMARDs, clinicians are faced with an increasingly challenging choice of treatment selection to achieve optimal disease management. Over time, 2 key questions have emerged: the comparative effectiveness of bDMARD monotherapy vs the combination of a bDMARD with methotrexate, and the comparative effectiveness of the available bDMARD either as monotherapy or in combination with methotrexate. The importance of these questions may be related to treatment efficacy and safety, given the diverse RA patient population among whom approximately one-third are treated with bDMARD monotherapy, primarily because of intolerance or noncompliance with methotrexate.5
The comparative effectiveness of bDMARD vs methotrexate monotherapy has been addressed in several studies. Overall, the superiority of bDMARD vs methotrexate monotherapy has been established for all 6 classes of bDMARDs, particularly in the setting of disease progression with methotrexate.6-9
With respect to the comparative effectiveness of bDMARD monotherapy vs combination with methotrexate, available studies have shown that some bDMARDs were more efficacious in combination with methotrexate, others as efficacious as either monotherapy or in combination, and the evidence for other DMARDs were less clear.
Specifically, the superiority of the efficacy of bDMARDs in combination with methotrexate compared to bDMARD monotherapy has been evident for tumor necrosis factor inhibitors (TNFis), but not non-TNFis.5,8 Both abatacept and tocilizumab have showed effectiveness whether combined with methotrexate or used as monotherapy.5,8,10 The effectiveness of rituximab as monotherapy compared to combination with methotrexate has been less clear, with some studies reporting superior efficacy as a combination,11-13 although the effectiveness either as monotherapy or in combination with methotrexate has also been reported.14 The use of tofacitinib in RA has been inconclusive because of lack of available data.5,15 Taken together, the evidence suggests that the currently available bDMARDs vs methotrexate monotherapy achieve greater control of disease activity. However, the combination of a bDMARD with methotrexate may be more efficacious than bDMARD monotherapy for anti-TNF agents, comparable for tocilizumab and abatacept, and inconclusive for rituximab, tofacitinib, and anakinra because of paucity of studies and data.
While it has been established that bDMARDs vs methotrexate may be more efficacious in disease control, the choice of available bDMARDs can be challenging because of the lack of head-to-head comparative studies and the limited data for use of these agents. The majority of the studies that have evaluated the comparative effectiveness of bDMARDs have concluded that anakinra may be the least efficacious.16 Furthermore, the American College of Rheumatology (ACR) response was found to be higher with tocilizumab compared to a TNFi or the JAK inhibitor tofacitinib.5 Among the TNFi agents, etanercept has been reported to be the most efficacious and infliximab the least.16,17 In combination with methotrexate, excluding anakinra, available data suggest comparable efficacy across the bDMARDs evaluated.10,18
A meaningful comparative effectiveness analysis of bDMARDs has been challenged by several limitations that question the accuracy of the comparisons.3 In many cases, there are variations in study design and clinical end points. Furthermore, available data may not be comparable for all agents; for example, there is fewer data for the newer approved agents such as the JAK inhibitors. Data has typically included heterogeneous, selected patient populations, with outdated definitions of clinical end points of clinical remission and low disease activity. Furthermore, in the absence of head-to-head studies, an indirect comparison of trial findings has often resulted in inconclusive analyses challenging clinical decision-making.
A recent systematic review and network meta-analysis by Janke et al provides a more rigorous comparative effectiveness analysis of the approved bDMARDs, using a method that included data from clinical study reports and reanalyses from individual patient data on key outcomes for RA, adopting the current definitions of clinical end points.3 This approach enabled a more homogeneous patient population for comparative analysis. The 34 studies that met the criteria for comparative effectiveness analyses included 10,869 patients and investigated 8 different biologic agents in combination with methotrexate (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab, anakinra, abatacept, and tocilizumab). However, the analysis did not include rituximab, or the more recently approved agents such as sarilumab, tofacitinib, baricitinib, and upadacitinib. Overall, as reported in previous studies, there were few statistically significant differences between the bDMARDs in combination with methotrexate in terms of benefits and harms.
Researchers found that anakinra was the least efficacious in clinical remission or low disease activity3; compared to anakinra, adalimumab, certolizumab pegol, and golimumab had statistically significant advantages for RA remission, and abatacept, adalimumab, infliximab, and tocilizumab were found to have statistically significant advantages for low disease activity.3 Regarding safety, certolizumab pegol had a higher risk for serious adverse events (compared to abatacept, adalimumab, anakinra, etanercept, and infliximab) and infections (compared to abatacept, anakinra, etanercept, golimumab, tocilizumab, and infliximab). The risk for serious infections was higher with infliximab compared to golimumab and tocilizumab. The discontinuation rate due to adverse events was higher for anakinra compared to abatacept, adalimumab, etanercept and infliximab, and higher for abatacept compared to tocilizumab.3 Despite the rigorous methodology of this study, the authors acknowledged the limited data for long-term direct comparisons between the bDMARDs, with a recommendation for routine availability of individual patient data.
Although the expansion of bDMARDs provides improved treatment options, selecting treatment for the optimal disease management has been challenging because of the limited robust comparative effectiveness studies available.
The recent rigorous study by Janke and colleagues suggest a small but statistically significant differences in disease remission, and serious adverse events between the biologic agents. From a clinical decision standpoint, it is important to individualize treatment, taking into consideration disease activity, comorbidities, and patient treatment preferences, while weighing the significance of the differences between the bDMARDs for disease management and outcomes.
Original post:
Comparing the Effectiveness of Biologic Agents in the Treatment of Rheumatoid Arthritis - Rheumatology Advisor
- Pharmacist explains best diet to reduce arthritis, inflammation and joint pain - The Mirror - March 10th, 2024
- Teen Raises Funds to Fight Arthritis - Arthritis Foundation - March 10th, 2024
- Is there a higher risk of depression among specific populations of patients with rheumatoid arthritis? - News-Medical.Net - March 10th, 2024
- Here's How to Explain Your Arthritis Pain to Your Doctor So They Actually Get It - Northwest Georgia News - March 10th, 2024
- Despite Their Prevalence, Arthritis, Neck and Back Pain Receive Few Research Dollars, Analysis Finds | BIDMC of ... - Beth Israel Deaconess Medical... - March 10th, 2024
- This Is the Difference Between Rheumatoid and Psoriatic Arthritis - Prescott Daily Courier - March 10th, 2024
- The #1 Early Sign of Arthritis Most People Miss, According to a Rheumatologist - Northwest Georgia News - March 10th, 2024
- The Efficacy and Safety of Apremilast in the Management of Psoriatic Arthritis: A Systematic Review and Meta-Analysis - Cureus - March 10th, 2024
- MU Researchers Participating in International Clinical Study Targeting Prevention of Osteoarthritis - University of Missouri School of Medicine - March 10th, 2024
- Review: Real-World Evidence Confirms Effectiveness and Safety of Adalimumab Biosimilar SB5 - The Center for Biosimilars - March 10th, 2024
- A Gender-Bias-Mitigated, Data-Driven Precision Medicine System to Assist in the Selection of Biological Treatments of ... - Cureus - March 10th, 2024
- Young arthritis cases are on the rise, new research suggests - The Examiner - March 10th, 2024
- Quiz: ACR Guideline for the Treatment of Psoriatic Arthritis - MD Magazine - February 10th, 2024
- Psoriatic arthritis: What to know about medications for children - Medical News Today - February 10th, 2024
- Ancient Egyptian woman had holes on her bones. Experts say its rare case of disease - Miami Herald - February 10th, 2024
- Arthritis and Pregnancy: Fertility, Gestation, Postpartum - Verywell Health - February 10th, 2024
- 3500-year-old burial of Nubian woman reveals 1 of world's earliest known cases of rheumatoid arthritis - Livescience.com - February 10th, 2024
- Impact of frailty severity and severe pain on cognitive function for community-dwelling older adults with arthritis: a cross ... - Nature.com - February 10th, 2024
- IHL-675A: Advancing Towards Innovative Arthritis Solutions, with Mark Bleackley, PhD - MD Magazine - February 10th, 2024
- Insomnia, Shorter Sleep Duration Linked to the Risk of Autoimmune Arthritis - MD Magazine - February 10th, 2024
- Advancements in Psoriatic Arthritis Treatment for Children: A Beacon of Hope - Medriva - February 10th, 2024
- Breakthrough Molecule RvT4 Reverses Inflammation and Clears Arterial Blockages in Rheumatoid Arthritis Patients - SciTechDaily - February 10th, 2024
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 10th, 2024
- EULAR Recommendations on Imaging in Crystal-Induced Arthropathies (CiA) - Medriva - February 10th, 2024
- The Importance of Ultrasound-Guided Synovial Biopsy in the Workup of Seronegative Inflammatory Arthritis: A Case ... - Cureus - February 10th, 2024
- Autoimmune diseases like lupus, MS, and rheumatoid arthritis strike far more women than men. Scientists now think they know why - Fortune - February 2nd, 2024
- Multiple Ulcers in the Ileum and Lymphadenopathy Following the Usage of Methotrexate in a Patient With Rheumatoid ... - Cureus - February 2nd, 2024
- These are the best arthritis creams of 2024, according to health experts - Yahoo Life - February 2nd, 2024
- Do Your Joints Ache When a Storm Is Brewing? Here's What's Really Happening - DISCOVER Magazine - February 2nd, 2024
- Olympic bronze medalist opens up about balancing arthritis with motherhood and triathlon - TRI247 - February 2nd, 2024
- Some Dinosaurs May Have Had Arthritis 90 Million Years Ago - IFLScience - February 2nd, 2024
- 3500-year-old remains of ancient Egyptian suffering from rheumatoid arthritis uncovered - Xinhua - February 2nd, 2024
- Lupus and other autoimmune diseases strike far more women than men. Now there's a clue why - The Associated Press - February 2nd, 2024
- Rheumatoid Arthritis Awareness Day on February 2: What you need to know - CNBCTV18 - February 2nd, 2024
- Rheumatoid Arthritis Awareness Day 2024: Signs, Symptoms, Diagnosis, and Prevention - News18 - February 2nd, 2024
- Improving arthritis in cold weather | Health Smart - WPMT FOX 43 - February 2nd, 2024
- Rheumatoid Arthritis Awareness Day: History, Significance And All You Need To Know - ABP Live - February 2nd, 2024
- Dietary Factors Tied to Osteoarthritis Pain | MedPage Today - Medpage Today - February 2nd, 2024
- Cold-weather coping tips for people with arthritis, osteoporosis and lung diseases - Southernminn.com - February 2nd, 2024
- How to manage arthritis and joint pain: Effective tips for knee pain relief - Health shots - February 2nd, 2024
- New study illuminates the genetics of thumb arthritis treatment - News-Medical.Net - January 25th, 2024
- Rheumatoid arthritis: 30 minutes of walking may lower blood pressure - Medical News Today - January 25th, 2024
- RA Disease Activity Assessed Too Little After Starting TNFi - Medscape - January 25th, 2024
- Lifestyle tips for youth's bone health: Avoid these habits to prevent arthritis - Hindustan Times - January 25th, 2024
- Best arthritis pain relief cream of 2024, according to experts - AOL - January 25th, 2024
- Vasculitis, an Early Unusual Presentation of Rheumatoid Arthritis: A Case Report - Cureus - January 25th, 2024
- Patients with later menarche, earlier menopause have higher risk for rheumatoid arthritis - Healio - January 25th, 2024
- Investigating Maternal Inflammatory Arthritis and Pregnancy Outcomes < Yale School of Medicine - Yale School of Medicine - January 25th, 2024
- Rheumatoid Arthritis and Diabetes: What's the Connection? - Health Central - January 25th, 2024
- Oxidative DNA Damage and Zinc Status in Patients With Rheumatoid Arthritis in Duhok, Iraq - Cureus - January 25th, 2024
- Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and Utilization of IL-17 Inhibitors - Yahoo Finance - January 25th, 2024
- The Connection Between Potassium and Rheumatoid Arthritis - Health Central - January 25th, 2024
- What Is the ACR20 (American College of Rheumatology) Criteria? - Health Central - January 25th, 2024
- RA Treatment Advances and Where They Are Headed - Health Central - January 25th, 2024
- TMC Medical Minutes- Arthritis & Cold Weather - KXII - January 25th, 2024
- How to deal with joint and arthritis pain in the cold weather - Crossroads Today - January 25th, 2024
- Arthritis: Regular exercises, calcium-rich diet and other habits to keep your bones strong and healthy - Moneycontrol - January 25th, 2024
- Men With Arthritis Have Higher Fertility Rates, Study Finds - Zenger.News - January 25th, 2024
- Pain on Top of Foot: 5 Causes, Swelling, Treatment - Verywell Health - January 25th, 2024
- Understanding Rheumatoid Arthritis in Women: Genetics, Hormones, and Impact - Medriva - January 25th, 2024
- Arthritis | Johns Hopkins Medicine - January 9th, 2024
- Ideal cardiovascular health metrics have better identification of arthritis - BMC Public Health - BMC Public Health - January 9th, 2024
- Acupuncture for Arthritis: Benefits and Risks - Verywell Health - January 9th, 2024
- Why do arthritic horses have more trouble during the winter? - EQUUS Magazine - January 9th, 2024
- Rather than roll over and die, I'm like, 'No, I still want to play': Steve Morse says arthritis diagnosis forced him to ... - Guitar.com - January 9th, 2024
- Top Signs that Your RA Treatment May No Longer Be Working - Health Central - January 9th, 2024
- What Is The Life Expectancy Of Rheumatoid Arthritis? A Review By Doctors - MSN - January 9th, 2024
- Nature Coast Orthopaedics | arthritis care | medicare and most insurance accepted | Beverly Hills, FL | chronicleonline ... - Citrus County Chronicle - January 9th, 2024
- Millions of arthritis patients could struggle to get blockbuster drug, as CVS pulls it from pharmacies - Daily Mail - January 9th, 2024
- What Is Arthritis? | Arthritis Foundation - May 17th, 2023
- Procedure to Surgery for Arthritis Is Recommended After First Failed Non-Operative Therapy - DocWire News - March 29th, 2023
- Higher Prevalence of Sarcopenia Reported in Patients with Rheumatoid Arthritis - Rheumatology Network - October 7th, 2022
- Exploring the Relationship Between Psoriatic Arthritis and Psoriasis - Dermatology Times - October 7th, 2022
- Are Tomatoes Bad For Arthritis? Here's What An MD Has To Say - Women's Health - October 7th, 2022
- Tocilizumab for Treating ICI-Induced Arthritis and Colitis - DocWire News - October 7th, 2022
- Why Arthritis Is A Clear And Present Danger, And How We Can Fight It - CNBCTV18 - October 7th, 2022
- Arthritis: Five cruciferous veg 'block inflammatory process' - backed by 10-year study - Express - October 7th, 2022
- 5 Exercise Habits for Arthritis in Your 50s - Eat This, Not That - October 7th, 2022
- Arthritis: 8 types of fish can cause acid crystals to build up in joints - 'very painful' - Express - October 7th, 2022
- EMA Issues Positive Opinion on the Safety of Filgotinib - Medscape - October 7th, 2022